Skip to main content
. 2022 May 27;36(7):e24517. doi: 10.1002/jcla.24517

TABLE 1.

Correlation between CD9 expression in tumor/stroma and clinicopathologic characteristics of PDAC patients in the non‐neoadjuvant and neoadjuvant group

Non‐neoadjuvant group (n = 211) Neoadjuvant group ‐ Fudan cohort (n = 98) Neoadjuvant group ‐ validation cohort (n = 81)
CD9 expression in tumor p CD9 expression in stroma p CD9 expression in tumor p CD9 expression in stroma p CD9 expression in tumor p CD9 expression in stroma p
Low High Negative Positive Low High Negative Positive Low High Negative Positive
Age 0.736 0.398 0.535 0.667 0.311 0.565
<Median 64 41 75 30 21 25 25 21 24 16 24 16
≥Median 67 39 70 36 27 25 26 26 20 21 22 19
Gender 0.638 0.295 0.310 0.222 0.232 0.704
Male 78 45 88 35 27 23 23 27 24 25 27 22
Female 53 35 57 31 21 27 28 20 20 12 19 13
Tumor location 0.365 0.217 0.563 0.940 0.965 0.175
Head&neck 69 37 77 29 21 19 21 19 20 17 18 19
Body&tail 62 43 68 37 27 31 30 28 24 20 28 16
Tumor differentiation 0.229 0.092 0.012 0.903 0.007 0.855
Well to moderate 75 39 84 30 35 24 31 28 33 17 28 22
Poor 56 41 61 36 13 26 20 19 11 20 18 13
Vascular invasion 0.291 0.633 0.098 0.140 0.032 0.236
No 88 48 95 41 31 24 25 30 32 20 27 25
Yes 43 32 50 25 17 26 26 17 12 17 19 10
Perineural invasion 0.143 0.609 0.269 0.480 0.243 0.697
No 32 27 39 20 12 8 9 11 16 9 15 10
Yes 99 53 106 46 36 42 42 36 28 28 31 25
Tumor size stage 0.147 0.740 0.281 0.057 0.590 0.037
1 38 16 35 19 16 10 13 13 9 10 6 13
2 59 34 66 27 22 25 20 27 24 16 25 15
3 34 30 44 20 10 15 18 7 11 11 15 7
Lymph node stage 0.807 0.834 0.051 0.143 0.033 0.070
0 55 31 58 28 28 17 19 26 29 15 20 24
1 52 31 59 24 15 26 26 15 13 15 19 9
2 24 18 28 14 5 7 6 6 2 7 7 2
TNM stage 0.687 0.602 0.044 0.021 0.046 0.028
I 47 25 47 25 22 11 11 22 21 10 12 19
II 60 37 70 27 21 32 34 19 21 20 27 14
III 24 18 28 14 5 7 6 6 2 7 7 2